

Report Template for Images with DaTscan™ (Ioflupane I 123 Injection)

GE Healthcare suggests following reporting guidelines such as those in the referenced Society of Nuclear Medicine Practice Guideline for Dopamine Transporter Imaging with ¹²³I-Ioflupane SPECT¹.

This includes, but is not limited to:

History

- State whether the patient used potentially interfering drugs, and if so, which drugs
- Describe the route, dosage, and timing of sedation in relation to the scan, if sedation was administered

Technique

- State the time that elapsed between tracer injection and acquisition
- State the injected radiopharmaceutical dose
- State what criteria are used for the report interpretation (eg, visual assessment, semi quantitative analysis, or comparison to reference database)

Diagnostic findings

- Mention any significant scan quality limitations, such as patient motion
- Describe the subjective visual impression of striatal binding compared with background activity. Examine both the caudate nuclei and the putamina for decreased activity; note which regions, if any, appear decreased. Note any significant asymmetries; mild asymmetry may occur in healthy individuals
- If abnormalities are present, report the location and intensity of the areas of decreased activity
- If semi quantitative analysis is performed, report the values and the reference range. An age-matched reference range would be preferable

Report conclusion

- The conclusion should state whether a presynaptic dopaminergic deficit is present or absent. Abnormal findings indicate a presynaptic striatal dopaminergic deficit


An example of a report outline based on this might look like the following:

Abnormal scan example

Technique: A thyroid-blocking agent was orally administered one hour prior to the intravenous administration of 4.8 mCi of 123-I-labeled DaTscan. Four hours later, a 30-minute SPECT scan of the brain was acquired. Data was reconstructed using iterative reconstruction and displayed in axial planes.

Findings: The images demonstrate reduced radiotracer uptake in the left and right striata, with more extensive involvement in the putamen, relative to caudate. Striatal reductions are more pronounced on the left caudate and putamen compared with the right.

Impression: Abnormal DaTscan image with evidence of striatal dopaminergic neurodegeneration.




Normal scan example

Technique: A thyroid-blocking agent was orally administered one hour prior to the intravenous administration of 5.0 mCi of 123-I-labeled DaTscan. Three hours later, a 30-minute SPECT scan of the brain was acquired. Data were reconstructed using iterative reconstruction and displayed in axial planes.

Findings: Bilateral, symmetric tracer uptake is noted in the striata. Nuclei uptake is distinct and above the background activity.

Impression: Normal and symmetric uptake of DaTscan in the striata without imaging evidence of striatal dopaminergic neurodegeneration.



Please consult full guidelines for further information. Additional practice guidelines may be available. The examples herein are for illustrative purposes only and are not intended to be exhaustive. Technician should use professional judgment and consider all other relevant factors in completing the report. Inclusion of additional information may be necessary or advisable.



Please see the [Product Indications, Important Safety Information,](#) and [full Prescribing Information.](#)

DaTscan™
Ioflupane I 123 Injection